

FOI REF: 22/097

8th March 2022

Tel: 0300 131 4500

Website: www.esht.nhs.uk

FREEDOM OF INFORMATION ACT

I am responding to your request for information under the Freedom of Information Act. The answers to your specific questions are as follows:

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

- **Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) as a single agent** 0
- **Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)** 0
- **Abemaciclib + Fulvestrant** 5
- **Anthracycline (e.g. doxorubicin or epirubicin) as a single agent** 0
- **Atezolizumab +Nab-paclitaxel/Paclitaxel** 0
- **Capecitabine as a single agent** 30
- **Carboplatin or Cisplatin as a single agent** 1
- **Eribulin as a single agent or in combination** 0
- **Everolimus + Exemestane** 0
- **Fulvestrant as a single agent** 0
- **Lapatinib** 0
- **Neratinib** 0
- **Parp Inhibitors (Olaparib/Talazoparib)** 0
- **Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)** 0
- **Palbociclib + Fulvestrant** 11
- **Pembrolizumab** 0
- **Pertuzumab + Trastuzumab + Docetaxel** 0
- **Ribociclib+Aromatase Inhibitor (e.g. anastrozole,exemestane,letrozole)** 0
- **Ribociclib + Fulvestrant** 3
- **Sacituzumab Govitecan** 0
- **Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent** 23
- **Trastuzumab as a single agent or in combination** 19

Cont.../

- **Trastuzumab emtansine** 12
- **Transtuzumab deruxtecan** 0
- **Vinorelbine as a single agent** 3
- **Any other active systemic anti-cancer therapy** 116

Q2. In the past 3 months, how many early/locally advanced (Stages I to IIIc) breast cancer patients were treated with an Aromatase Inhibitor (anastrozole, exemestane, letrozole) as a single agent?

0

If I can be of any further assistance, please do not hesitate to contact me.

Should you be dissatisfied with the Trust's response to your request, please write to the Freedom of Information Department (esh-tr.foi@nhs.net), quoting the above reference.

Yours sincerely

Linda Thornhill (Mrs)
Corporate Governance Manager
esh-tr.foi@nhs.net